Evidence map›Paper›PMID 39200368›Full record

ArticleBiomedicines2024

BP1003 Decreases STAT3 Expression and Its Pro-Tumorigenic Functions in Solid Tumors and the Tumor Microenvironment.

Maria Gagliardi, Rhonda Kean, Bingbing Dai, Jithesh Jose Augustine, Michael Roberts, Jason Fleming, D Craig Hooper, Ana Tari Ashizawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maria GagliardiBio-Path Holdings Inc., Bellaire, TX 77401, USA.
Rhonda KeanDepartment of Cancer Biology, Philadelphia, Thomas Jefferson University, PA 19107, USA.
Bingbing DaiDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jithesh Jose AugustineDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michael RobertsBio-Path Holdings Inc., Bellaire, TX 77401, USA.
Jason FlemingDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
D Craig HooperDepartment of Cancer Biology, Philadelphia, Thomas Jefferson University, PA 19107, USA.ORCID 0000-0002-8578-5104
Ana Tari AshizawaBio-Path Holdings Inc., Bellaire, TX 77401, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Overexpression and aberrant activation of signal transducer and activator of transcription 3 (STAT3) contribute to tumorigenesis, drug resistance, and tumor-immune evasion, making it a potential cancer therapeutic target. BP1003 is a neutral liposome incorporated with a nuclease-resistant P-ethoxy antisense oligodeoxynucleotide (ASO) targeting the STAT3 mRNA. Its unique design enhances BP1003 stability, cellular uptake, and target affinity. BP1003 efficiently reduces STAT3 expression and enhances the sensitivity of breast cancer cells (HER2

Indexed as

antisense oligodeoxynucleotidebreastM2 macrophagesmonocyte polarizationovarianpancreatic cancerSTAT3

Identifiers

PMID39200368
PMCPMC11351911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.